OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Olink Proteomics is a Swedish company with strong global presence, that enables high-plex protein biomarker discovery and development. Olink’s platform currently has the ability to robustly measure ~5,400 analytes. It’s been used in different settings due to its scalability and actionability such as in the elucidation of pathways and mechanisms of drug action, as a screening tools for identifying signatures/biomarkers with a prognostic/predictive significance as well as to safety and toxicity studies, drug target selection and differentiation. Due to the fact that the protein library, which continuously expands, covers all major biological pathways the applications are in numerous disease areas, such as, Cardiology, Diabetes Immuno-oncology and Neurology.
In this scientific seminar they will go through a series of case studies elucidating the power of their capabilities: * How Olink technology enables biomarker identification, precision medicine and multiOmics approaches. * Examples of Olink technology applied in specific human disease areas.
